AB-161

AB-161 is an orally active HBV RNA destabilizer and a PAPD5/7 inhibitor, with its primary action focused in the liver. AB-161 treats Hepatitis B Virus (HBV) infection by lowering the levels of Hepatitis B surface antigen (HBsAg), with an EC50 value of 2.2 nM for HBsAg. AB-161 can be used in the field of HBV infection research[1].

Product Specifications

CAS Number

[2848560-66-5]

UNSPSC

12352005

Target

HBV

Type

Reference compound

Related Pathways

Anti-infection

Field of Research

Infection

Assay Protocol

https://www.medchemexpress.com/ab-161.html

Smiles

O=C(O)C1=CC2=C(C3=C(C[C@H]2C(C)(C)C)N4C(C(OC(F)F)=CC(OC)=C4)=N3)NC1=O

Molecular Formula

C21H21F2N3O5

Molecular Weight

433.41

References & Citations

[1]Gotchev D, et al. Structure-Activity Relationships and Discovery of (S) -5- (tert-Butyl) -11- (difluoromethoxy) -9-methoxy-2-oxo-1,2,5,6-tetrahydropyrido[2',1':2,3]imidazo[4,5-h]quinoline-3-carboxylic Acid (AB-161), a Novel Orally Available and Liver-Centric HBV RNA Destabilizer. J Med Chem. 2024 Nov 28;67 (22) :20467-20494.